MRK
MRNA
Why the stock is buzzing
Moderna isn’t just getting a random after-hours love tap here. The move came after the company said three abstracts on intismeran autogene, its individualized mRNA neoantigen therapy, were accepted for presentation at the European Society for Medical Oncology Congress 2026 in Madrid.
The headliner: melanoma data
The big one is the Presidential Symposium abstract tied to Phase 3 INTerpath-001. That trial is testing intismeran autogene plus Merck’s pembrolizumab against pembrolizumab alone in patients with resected stage IIB-IV melanoma. Translation: Moderna is trying to show its custom cancer vaccine can meaningfully raise the bar in a very tough disease area.
Why investors care
This is the kind of update that gets biotech traders leaning forward in their chairs. Not because it’s a final approval or a revenue print, but because conference season is where promising oncology programs either start to look like real businesses or fade into the “nice idea” pile.
- The lead abstract gets a Presidential Symposium slot, which is biotech’s version of prime time.
- Two more posters will cover pancreatic cancer and early-stage non-small cell lung cancer.
- The stock was already up sharply on the day, so the market clearly wanted a reason to keep the party going.
Big picture
For Moderna, this is another reminder that the post-vaccine identity crisis is still very much on. The company wants investors to see it as a serious oncology player, and this ESMO presentation is one more chance to make that case without having to yell over the crowd.